CLL Coverage from Every Angle

Matthew S. Davids, MD, on Clinical Implications of New Data on Newer CLL Therapies

Posted: Tuesday, December 8, 2020

Matthew S. Davids, MD, of Dana-Farber Cancer Institute, discusses overarching insights on newer therapies such as ibrutinib and venetoclax for chronic lymphocytic leukemia, how the different regimens apply to first-line vs the relapsed/refractory settings, and other clinical pearls from three pivotal studies.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.